ReviewReviews in the neurosciences2022
Modifying the diet and gut microbiota to prevent and manage neurodegenerative diseases.
Review in Reviews in the neurosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Current insights and trends in atopic dermatitis and microbiota interactions: a systematic review and bibliometric analysis.Frontiers in microbiology · 2025Pooled it
- The Neuroprotective Effect of a Waste Byproduct Obtained From Pomegranate (Punica granatum).Phytotherapy research : PTR · 2026Review
- Exploring the associations between lifestyle and dietary patterns with preclinical alzheimer's disease: findings from La Rioja cohort study.European journal of nutrition · 2026Article
- Microbial enterotype is linked to episodic and working memories via brain function in the parietal and occipital cortices.BMC biology · 2026Article
- Gut-Brain Signaling in Parkinson's Disease: A Narrative Review.International journal of molecular sciences · 2026Review
- The gut-brain axis: mechanisms linking intestinal dysbiosis with stroke.Frontiers in cell and developmental biology · 2026Review
- Special Issue: "Molecular Research in Human Microbiome 2.0".International journal of molecular sciences · 2025Article
- Gut Permeability and Microbiota in Parkinson's Disease: Mechanistic Insights and Experimental Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Review
- The Gut-Brain Axis in Brain Tumors: Insights into Tumor Development, Progression, and Therapy.Biomedicines · 2025Review
- Effects of three different dietary β-gulcans supplementation on the microbiota composition and short-chain fatty acid production in mice.BMC nutrition · 2025Article
- Moderate Beer Consumption Ameliorated Aging-Related Metabolic Disorders Induced by D-Galactose in Mice via Modulating Gut Microbiota Dysbiosis.Food science & nutrition · 2025Article
- Relationship Between Dietary Habits and Stress Responses Exerted by Different Gut Microbiota.Nutrients · 2025Article
- Potential benefits of kefir and its compounds on Alzheimer's disease: A systematic review.Brain behavior and immunity integrative · 2025Article
- The gut microbiota influences neurodegenerative diseases through the gut-brain axis: molecular mechanisms and effects on immune function.Frontiers in immunology · 2025Review
- Microbiome-targeted Alzheimer's interventions via gut-brain axis.Frontiers in microbiology · 2025Review
- Article
- A comprehensive review on the pharmacological role of gut microbiome in neurodegenerative disorders: potential therapeutic targets.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Involvement of Aryl Hydrocarbon Receptor in Longevity and Healthspan: Insights from Humans, Mice, andInternational journal of molecular sciences · 2024Article
- Pomegranate (Molecules (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of Alzheimer's disease and Parkinson's disease is steadily increasing due to the aging population. The lack of effective drugs against these neurodegenerative disorders makes it imperative to identify new strategies for their prevention and treatment. Recent studies have revealed that harnessing the power of the gut microbiota through modification of diet may be a valuable approach for reducing the risk, modulating the symptoms, and ameliorating the pathophysiological aspects of neurodegenerative diseases. Consuming specific dietary components can alter the prevalence of bacterial communities within the gut to a healthy enterotype, which can influence the production of beneficial metabolites by microbiota. This article focuses on several dietary components, which have been demonstrated to affect the gut microbiota-brain axis and therefore could lead to attenuation of specific pathological processes in neurodegenerative diseases. Published evidence indicates that fermented foods, including kefir, and foods that are high in bioactive polyphenols and complex carbohydrates, such as grapes, pomegranates, and seaweed, may be effective at reducing neuroinflammation, oxidative stress, neurotransmitter dysfunction, and neuronal death associated with Alzheimer's and Parkinson's diseases. Even though experimental evidence supporting the protective properties of the above dietary components in these diseases is emerging, it is evident that further human clinical studies are required to conclusively establish the benefits of any suggested dietary interventions. The translational potential of such research is illustrated by the clinical success of the recently developed Alzheimer's drug, GV-971, which is a seaweed derivative that works by modulating the gut microbiota-brain axis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.